AMENDMENT TO THE CLAIMS:

Claim 25 is hereby amended to independent form. This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1.–17. (Cancelled)

18. (Previously Presented) A method of treating a human liver cancer which comprises the intrahepatic administration of a therapeutically effective amount of methoxymorpholino doxorubicin (MMDX) to a patient in need thereof, wherein said MMDX is administered as an infusion of from about 15 minutes to about 30 minutes every 4 weeks.

19. (Previously Presented) A method for reducing methoxymorpholino doxorubicin systemic exposure of a patient suffering from a liver cancer which comprises the intrahepatic administration of a therapeutically effective amount of methoxymorpholino doxorubicin (MMDX) to said patient, wherein said MMDX is administered as an infusion of from about 15 minutes to about 30 minutes every 4 weeks.

20. (Previously Presented) The method according to claim 18, wherein the liver tumor is a tumor primarily confined to the liver.

21. (Previously Presented) The method according to claim 20, wherein the tumor primarily confined to the liver is a hepatocellular carcinoma (HCC) or a cholangiocarcinoma.

22. (Previously Presented) The method according to claim 18, wherein the tumor is a liver metastasis.

23. (Previously Presented) The method according to claim 18, wherein the intrahepatic administration of MMDX is via the hepatic artery.

24. (Cancelled)

25. (Currently Amended) The method ~~according to claim 18,~~ of treating a human liver cancer which comprises the intrahepatic administration of a therapeutically effective amount of methoxymorpholino doxorubicin (MMDX) to a patient in need thereof, wherein MMDX is administered as a 5-10 minute bolus every 8 weeks.

26. (Previously Presented) The method according to claim 18, wherein MMDX is administered with an agent, which remains selectively in a liver tumor after its injection into the hepatic artery.

27. (Previously Presented) The method according to claim 26, wherein the agent is iodized oil.

28. (Previously Presented) The method according to claim 18, wherein MMDX is administered in a dose ranging from about 100 mcg/m^2 to about 1000 mcg/m^2.

29. (Previously Presented) The method according to claim 28, wherein MMDX is administered in a dose ranging from about 100 mcg/m^2 to about 800 mcg/m^2.

30. (Previously Presented) The method according to claim 29, wherein the dose is 200 mcg/m^2.

31. (Previously Presented) A method of treating human liver tumor, which comprises the intrahepatic administration of a therapeutically effective amount of a pharmaceutical composition which comprises as an active principle methoxymorpholino doxorubicin (MMDX) and a pharmaceutically acceptable agent which remains selectively in a liver tumor after its

injection into the hepatic artery, wherein said MMDX is administered as a 5 to 10 minutes bolus every 8 weeks.

32. (Previously Presented) A method of treating a human liver tumor which comprises the intrahepatic administration of a therapeutically effective amount of methoxymorpholino doxorubicin (MMDX) to a patient in need thereof, wherein said MMDX is administered as a 5 to 10 minutes bolus every 8 weeks.

33. (Previously Presented) A method for reducing methoxymorpholino doxorubicin systemic exposure of a patient suffering from a liver cancer which comprises the intrahepatic administration of a therapeutically effective amount of methoxymorpholino doxorubicin (MMDX) to said patient, wherein said MMDX is administered as a 5 to 10 minutes bolus every 8 weeks.

34. (Previously Presented) A pharmaceutical composition for the treatment of a human liver cancer by intrahepatic administration via injection into the hepatic artery comprising:

a) methoxymorpholino doxorubicin (MMDX) in an amount sufficient to provide a dosage of about 100 mcg/m^2 to about 1000 mcg/m^2; and

b) a pharmaceutically acceptable agent which remains selectively in a liver tumor after its injection into the hepatic artery.

35. (Previously Presented) The pharmaceutical composition of claim 34 wherein the MMDX is in an amount sufficient to provide a dosage of about 100mcg/m^2 to about 800 mcg/m^2.

36. (Previously Presented) The pharmaceutical composition of claim 34 wherein the MMDX is in an amount sufficient to provide a dosage of about 200mcg/m^2.

37. (Previously Presented) The pharmaceutical composition of claim 34 wherein the agent is iodized oil.